<?xml version="1.0" encoding="UTF-8"?>
<p id="p0635">CoVs have two viral enzymes, M
 <sup>pro</sup> and PL
 <sup>pro</sup>, that are cysteine protease involved in the formation of structural and non-structural proteins that constitute the viruses and favour control of host cells.
 <xref rid="b1570" ref-type="bibr">
  <sup>314</sup>
 </xref> DSF, as mentioned, can covalently modify cysteine residues interfering with viral replication
 <xref rid="b1565" ref-type="bibr">313</xref>, 
 <xref rid="b1575" ref-type="bibr">315</xref> investigated whether DSF can inhibit MERS-CoV and SARS-CoV PL
 <sup>pro</sup> by measuring the deubiquitinating (DUB) activity of PL
 <sup>pro</sup> in the presence of different concentrations of DSF. DSF showed a dose-dependent inhibitory effect with IC
 <sub>50</sub> values of 14.6 µM for MERS-CoV, and 24.1 µM for SARS-CoV. Different assays, such as proteolytic and binding synergy assays, were also conducted and described.
 <xref rid="b1565" ref-type="bibr">
  <sup>313</sup>
 </xref> Although outcomes indicate DSF for anti-MERS-CoV and anti-SARS-CoV therapy, to the present date (15th June 2020), no other article was published claiming the availability of the compound as promising anti-SARS-CoV-2.
</p>
